Evidence map›Paper›PMID 36966051›Full record

Trial reportParkinsonism & related disorders2023

Interactive mobile application for Parkinson's disease deep brain stimulation (MAP DBS): An open-label, multicenter, randomized, controlled clinical trial.

Gordon Duffley, Aniko Szabo, Barbara J Lutz, Emily C Mahoney-Rafferty, Christopher W Hess, Adolfo Ramirez-Zamora, Pamela Zeilman, Kelly D Foote, Shannon Chiu, Michael H Pourfar and 18 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Parkinsonism & related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Gordon DuffleyScientific Computing and Imaging Institute, University of Utah, Salt Lake City, UT, USA; Department of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA.
Aniko SzaboDivision of Biostatistics, Institute for Health & Equity, Medical College of Wisconsin, Milwaukee, WI, USA.
Barbara J LutzSchool of Nursing, University of North Carolina-Wilmington, Wilmington, NC, USA.
Emily C Mahoney-RaffertyNorman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville, FL, USA.
Christopher W HessNorman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville, FL, USA.
Adolfo Ramirez-ZamoraNorman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville, FL, USA.
Pamela ZeilmanNorman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville, FL, USA.
Kelly D FooteNorman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville, FL, USA.
Shannon ChiuNorman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville, FL, USA.
Michael H PourfarCenter for Neuromodulation, New York University Langone Medical Center, New York, NY, USA.
Clarisse Goas CnpDepartment of Neurology, Wake Forest School of Medicine, Winston Salem, NC, USA.
Jennifer L WoodDepartment of Neurology, Wake Forest School of Medicine, Winston Salem, NC, USA.
Ihtsham U HaqDepartment of Neurology, University of Miami, Miami, FL, USA.
Mustafa S SiddiquiDepartment of Neurology, Wake Forest School of Medicine, Winston Salem, NC, USA.
Mitra AfshariDepartment of Neurological Sciences, Section of Movement Disorders, Rush University, Chicago, IL, USA.
Melissa HeiryWeill Institute of Neurosciences, UCSF Movement Disorder and Neuromodulation Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Jennifer ChoiWeill Institute of Neurosciences, UCSF Movement Disorder and Neuromodulation Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Monica VolzWeill Institute of Neurosciences, UCSF Movement Disorder and Neuromodulation Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Jill L OstremWeill Institute of Neurosciences, UCSF Movement Disorder and Neuromodulation Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Marta San LucianoWeill Institute of Neurosciences, UCSF Movement Disorder and Neuromodulation Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Nicki NiemannDepartment of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
Andrew BillnitzerDepartment of Neurology, Baylor College of Medicine, Houston, TX, USA.
Daniel SavittDepartment of Neurology, Baylor College of Medicine, Houston, TX, USA.
Arjun TarakadDepartment of Neurology, Baylor College of Medicine, Houston, TX, USA.
Joohi Jimenez-ShahedDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Camila C AquinoDepartment of Neurology, University of Utah, Salt Lake City, UT, USA; Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
Michael S OkunNorman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville, FL, USA.
Christopher R ButsonScientific Computing and Imaging Institute, University of Utah, Salt Lake City, UT, USA; Department of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA; Norman Fixel Institute for Neurological Diseases, Program for Movement Disorders and Neurorestoration, Departments of Neurology and Neurosurgery, University of Florida, Gainesville, FL, USA; Department of Neurology, University of Utah, Salt Lake City, UT, USA; Departments of Neurosurgery, and Psychiatry, University of Utah, Salt Lake City, UT, USA. Electronic address: butsonc@ufl.edu.

Funding

Mobile Decision Support System for Nurse Management of Neuromodulation TherapyR01NR014852 · NINR · UNIVERSITY OF UTAH · PI BUTSON, CHRISTOPHER R, OKUN, MICHAEL S · 2015 to 2019
$2.9M
NINR NIH HHS R01 NR014852
6 · The paper itself

Abstract

introductionDeep brain stimulation (DBS) is an effective treatment for Parkinson's disease (PD), but its efficacy is tied to DBS programming, which is often time consuming and burdensome for patients, caregivers, and clinicians. Our aim is to test whether the Mobile Application for PD DBS (MAP DBS), a clinical decision support system, can improve programming.

methodsWe conducted an open-label, 1:1 randomized, controlled, multicenter clinical trial comparing six months of SOC standard of care (SOC) to six months of MAP DBS-aided programming. We enrolled patients between 30 and 80 years old who received DBS to treat idiopathic PD at six expert centers across the United States. The primary outcome was time spent DBS programming and secondary outcomes measured changes in motor symptoms, caregiver strain and medication requirements.

resultsWe found a significant reduction in initial visit time (SOC: 43.8 ± 28.9 min n = 37, MAP DBS: 27.4 ± 13.0 min n = 35, p = 0.001). We did not find a significant difference in total programming time between the groups over the 6-month study duration. MAP DBS-aided patients experienced a significantly larger reduction in UPDRS III on-medication scores (-7.0 ± 7.9) compared to SOC (-2.7 ± 6.9, p = 0.01) at six months.

conclusionMAP DBS was well tolerated and improves key aspects of DBS programming time and clinical efficacy.

Indexed as

Deep Brain StimulationMobile ApplicationsParkinson DiseaseSubthalamic NucleusAdultAgedAged, 80 and overHumansMiddle AgedTreatment Outcome

Identifiers

PMID36966051
PMCPMC11265292

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.